This study is for adults with pleural mesothelioma, a type of cancer in the lining of the lungs, that cannot be removed by surgery. The study compares a new treatment, **Volrustomig (MEDI5752)** combined with **Carboplatin** and **Pemetrexed**, to other treatments chosen by doctors. **Carboplatin** and **Pemetrexed** are chemotherapy drugs that help kill cancer cells. **Nivolumab** and **Ipilimumab** are medicines that help the immune system fight cancer. Patients must be 18 or older, with confirmed pleural mesothelioma, and in good health except for their cancer. They cannot participate if they have other severe illnesses or infections like tuberculosis or hepatitis. The study might have risks like side effects from the drugs, but it can also offer the possibility of receiving a new treatment that could be effective.

• Participation involves being randomly assigned to different treatment groups.
• Must not have other serious illnesses or infections.
• Potential risks include drug side effects, but it offers a chance to try new treatment.